Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > The floodgates for massive dilution has been fully opened.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by TheBearInTheWoodson Jun 16, 2022 12:04am
85 Views
Post# 34760252

RE:The floodgates for massive dilution has been fully opened.

RE:The floodgates for massive dilution has been fully opened.

I can't believe my favourite AGN bag holder, the one that was pumping the tires here about going to the Nasdaq with ZERO patents and a failure human trial is starting to turn negative! 

You bought in at .35 and it is currently at .05 before the 100-1 consolidation. Now it is limitless dilution with a warrant to boot! 


Poor bag holder, please give more advice on what to invest in so we can stay the hell away from it! What a nightmare for shareholders.... 

And the best part is that Mackie is performing the PP! The same firm that removed coverage after the last failed trial! Management is desperate, but someone has to pay the obscene salaries!! 

DONT BUY COMPANIES THAT INSIDERS DONT OWN!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities